Effect of Recombinant Interleukin-21 on the Lymph Node Pathology in Patients With Stage III Melanoma.
The decision to discontinue the NN028-1801 trial is not due to any safety concerns. The
trial was terminated as a result of a strategic decision by the sponsoring company.
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Complete pathological response rate in the lymph nodes
after 4 weeks of treatment
Paul Kristjansen, MD, PhD, DMSc
Germany: Federal Institute for Drugs and Medical Devices